A $46 Million Bet on a New Way to Treat Kidney Disease

Jan de Vries · 2026-08-07

A biotech company in Glasgow just landed a serious chunk of change to take on one of the most common inherited kidney diseases out there. Mironid, a company spun out of Scottish universities, has closed a $46 million Series B round. That money is going straight into clinical trials for a drug candidate that could change how we treat Autosomal Dominant Polycystic Kidney Disease, or ADPKD. ### Why This Funding Round Matters For those who haven't heard of ADPKD, it's a genetic disorder where fluid-filled cysts grow unchecked in the kidneys. Over time, these cysts can destroy kidney function. Neil Wilkie, Mironid's CEO, put it bluntly: it's the most common hereditary kidney disorder, affecting over 12 million people globally. Half of those patients will face kidney failure by age 60. That's a stark reality, and it's exactly why this funding is such a big deal. The round was led by the Scottish National Investment Bank, with backing from heavy hitters like Roche Venture Fund, Sofinnova Partners, and BioGeneration Ventures. When you see that kind of syndicate, it's a signal that the science is credible. It's not just about the money; it's about validation from people who know what they're looking at. ### A Different Approach to Cyst Growth So what's Mironid doing differently? Their lead candidate targets something called cyclic AMP, or cAMP. That's a cellular signal that's active at every stage of the disease, from the very start all the way to end-stage. It drives both the proliferation of cells and the secretion of fluid inside the cysts. By going after this pathway directly, Mironid thinks it can stop new cysts from forming and halt the growth of existing ones. Preclinical data looks promising. The company reports significant reductions in cyst number and kidney volume, with a safety profile that seems favorable. The idea is that this could be a more durable option with fewer side effects than what's currently on the market. That's the hope, anyway. Clinical trials will be the real test. ### The Story Behind the Company Mironid isn't a flash in the pan. It was spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. That's a long runway of academic work. The company is headquartered in Glasgow and focuses on degenerative and rare genetic kidney diseases, plus major inflammatory conditions and cancer. Beyond ADPKD, the pipeline includes work on phosphodiesterase 4 (PDE4) enzymes, which play a role in cell signaling pathways tied to disease progression. It's a research-and-development-led model, funded through venture capital and strategic investment, with an eye on moving programs from the lab through clinical trials and eventually to commercialization. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed it up nicely: "Mironid exemplifies Scotland's growing reputation for biotech innovation." He's not wrong. The country has been punching above its weight in life sciences, and this kind of investment helps cement that reputation. ### What Happens Next This fresh capital follows an earlier Series A extension, bringing Mironid's total funding since inception to about $47 million. The immediate priority is advancing the lead candidate through clinical development. For the 12 million people living with ADPKD, the hope is that this research translates into something real. It's early days, but the pieces are in place. Now it's about execution. - Lead investor: Scottish National Investment Bank - Total funding to date: Approximately $47 million - Focus: First-in-class treatment for ADPKD - Key science: Targeting cAMP to stop cyst growth The road from here to a commercial therapy is long and uncertain. But with this kind of backing, Mironid has a real shot at making a difference. And for a disease that affects so many, that's worth paying attention to.